First line combination therapy improves progression-free survival in advanced lung cancer

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

First line combination therapy improves progression-free survival in advanced lung cancer

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase ...

Thu 7 Dec 17 from Medical Xpress

First line combination therapy improves progression-free survival in advanced lung cancer, Thu 7 Dec 17 from Eurekalert

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer, Thu 7 Dec 17 from AlphaGalileo

Novel compound restores immune response in patients with melanoma

A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

Fri 8 Dec 17 from Eurekalert

Researchers discover resistance mechanism to checkpoint inhibitors and how to reverse it

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology ...

Fri 8 Dec 17 from Eurekalert

  • Pages: 1

Bookmark

Bookmark and Share